CRVS Corvus Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1626971 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-326.6%
TTM EPS YoY-33.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-45.9%
ROA-42.3%
ROIC (approx.)-40.8%
Asset turnover—
Leverage & solvency
Liabilities / assets6.9%
Debt / equity0.00x
Current ratio13.38x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.73x
Accruals ratio-11.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20212022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $33.72M | $19.39M | $16.53M | $24.47M | $29.11M |
| SG&A expense | $9.25M | $8.16M | $6.88M | $8.10M | $9.52M |
| Operating income | -$42.97M | -$27.55M | -$23.41M | -$32.56M | -$38.63M |
| Pretax income | -$13.32M | -$59.10M | -$21.75M | -$31.30M | -$43.24M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$15.28M | -$62.29M | -$27.03M | -$41.31M | -$43.24M |
| EBITDA | -$42.87M | -$27.46M | -$23.26M | -$32.20M | -$38.17M |
| EPS (basic) | -0.19 | -1.02 | -0.56 | -0.89 | -1.03 |
| EPS (diluted) | -0.53 | -1.02 | -0.56 | -0.89 | -1.03 |
| Weighted avg. shares (diluted) | 79.74M | 60.99M | 48.03M | 46.55M | 41.85M |
| Balance sheet | |||||
| Cash & equivalents | $4.58M | $8.74M | $12.62M | $13.16M | $63.46M |
| Short-term investments | $52.17M | $43.22M | — | — | — |
| Receivables | $37,000 | $75,000 | $26,000 | $588,000 | — |
| Current assets | $58.21M | $54.41M | $27.96M | $43.66M | $71.31M |
| PP&E, net | $220,000 | $151,000 | $236,000 | $353,000 | $451,000 |
| Total assets | $71.12M | $68.91M | $45.55M | $68.24M | $109.45M |
| Current liabilities | $9.38M | $35.40M | $6.87M | $10.75M | $9.69M |
| Total liabilities | $9.91M | $36.34M | $6.87M | $12.12M | $12.29M |
| Shareholders' equity | $61.20M | $32.57M | $38.68M | $56.12M | $97.16M |
| Shares outstanding | 74.70M | 67.90M | 49.04M | 46.55M | 46.55M |
| Cash flow statement | |||||
| Operating cash flow | -$32.80M | -$25.42M | -$23.93M | -$27.02M | -$36.72M |
| Capital expenditure | $174,000 | — | $34,000 | $269,000 | $5,000 |
| Free cash flow | -$32.97M | — | -$23.97M | -$27.29M | -$36.72M |
| Investing cash flow | -$7.80M | -$27.48M | $15.54M | -$23.28M | $21.56M |
| Financing cash flow | $36.43M | $49.03M | $7.86M | $0 | $62.16M |
| Depreciation & amortization | $105,000 | $85,000 | $151,000 | $367,000 | $460,000 |
| Stock-based compensation | $5.33M | $3.00M | $2.15M | $2.69M | $4.23M |
Free plan shows the latest 5 periods; Pro shows all 12 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.